Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 1/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.40 |
| ▸ | AR | P10275 | 2/20 | 0.39 |
| ▸ | SNCA | P37840 | 1/20 | 0.36 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 4/20 | 0.34 |
| ▸ | MAOA | P21397 | 3/20 | 0.34 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16955571 | 0.84 | GRM4 (0.37) | CYP11B1CYP11B2ARSNCAMAOB | |
| SCHEMBL8156844 | 0.81 | MAOB (0.44) | CYP11B1CYP11B2ARSNCATRPV4 | |
| SCHEMBL24108550 | 0.80 | CYP11B1 (0.40) | CYP11B1CYP11B2SNCATRPV4MAOB | |
| SCHEMBL7135612 | 0.80 | MAOB (0.38) | SNCATRPV4MAOBMAOA | |
| SCHEMBL2997723 | 0.78 | SNCA (0.49) | CYP11B1CYP11B2ARSNCATRPV4 | |
| SCHEMBL536160 | 0.76 | TSHR (0.43) | CYP11B1CYP11B2AR | |
| SCHEMBL7571054 | 0.76 | MAOB (0.41) | CYP11B1CYP11B2ARSNCATRPV4 | |
| SCHEMBL5099511 | 0.76 | TRPV4 (0.52) | CYP11B1CYP11B2ARTRPV4MAOB | |
| SCHEMBL3164050 | 0.76 | CYP11B1 (0.58) | CYP11B1CYP11B2ARTRPV4MAOB | |
| SCHEMBL12062549 | 0.73 | TSHR (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1276726-A2 | SUBSTITUTED PHENYL FARNESYLTRANSFERASE INHIBITORS | Abbott Laboratories (US) | 2003-01-22 | — | — | EP | disclosed |
| US-20020019527-A1 | Substituted phenyl farnesyltransferase inhibitors | ABBOTT LABORATORIES | 2002-02-14 | — | — | US | disclosed |
| WO-2001081316-A2 | SUBSTITUTED PHENYL FARNESYLTRANSFERASE INHIBITORS | ABBOTT LABORATORIES (US) | 2001-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020019527-A1 | Substituted phenyl farnesyltransferase inhibitors | FNTA, FNTB, SLC10A1 | CYP11B1 94/4885CYP11B2 203/4885AR 4525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.